Your browser is no longer supported. Please, upgrade your browser.
BBI Brickell Biotech, Inc. daily Stock Chart
Brickell Biotech, Inc.
Index- P/E- EPS (ttm)-12.57 Insider Own2.30% Shs Outstand9.11M Perf Week-6.49%
Market Cap23.33M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.67M Perf Month-20.76%
Income-23.60M PEG- EPS next Q- Inst Own11.40% Short Float2.04% Perf Quarter-10.10%
Sales5.50M P/S4.24 EPS this Y13.60% Inst Trans40.58% Short Ratio0.11 Perf Half Y-35.52%
Book/sh0.65 P/B1.44 EPS next Y- ROA- Target Price- Perf Year-82.88%
Cash/sh0.28 P/C3.29 EPS next 5Y- ROE- 52W Range0.88 - 6.51 Perf YTD-37.67%
Dividend- P/FCF- EPS past 5Y19.10% ROI-291.40% 52W High-85.57% Beta-0.12
Dividend %- Quick Ratio1.80 Sales past 5Y-12.30% Gross Margin- 52W Low6.56% ATR0.15
Employees15 Current Ratio1.80 Sales Q/Q-71.40% Oper. Margin- RSI (14)40.61 Volatility4.87% 12.39%
OptionableNo Debt/Eq0.00 EPS Q/Q-104.50% Profit Margin- Rel Volume0.99 Prev Close0.94
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume1.47M Price0.94
Recom3.00 SMA20-20.11% SMA50-20.23% SMA200-50.15% Volume309,325 Change0.47%
Jun-17-20 10:00PM  
Jun-15-20 06:30AM  
May-31-20 08:04AM  
May-13-20 04:01PM  
May-04-20 04:05PM  
Mar-18-20 04:01PM  
Mar-09-20 04:05PM  
Mar-04-20 06:30AM  
Feb-20-20 11:43AM  
Feb-18-20 06:30AM  
Jan-10-20 04:05PM  
Nov-13-19 04:05PM  
Oct-30-19 04:42PM  
Sep-03-19 06:45AM  
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead products candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. The company was founded in 2009 and is based in Boulder, Colorado.